精華(hua)制(zhi)(zhi)藥(yao)集團股(gu)份(fen)有(you)限公司是由南(nan)通(tong)(tong)(tong)產控集團控股(gu)、國(guo)資(zi)監管(guan)的地方國(guo)有(you)控股(gu)企業(ye),由原南(nan)通(tong)(tong)(tong)中誠制(zhi)(zhi)藥(yao)有(you)限公司(南(nan)通(tong)(tong)(tong)中藥(yao)廠(chang))變(bian)更(geng)、重組南(nan)通(tong)(tong)(tong)制(zhi)(zhi)藥(yao)總廠(chang)(南(nan)通(tong)(tong)(tong)制(zhi)(zhi)藥(yao)廠(chang)、南(nan)通(tong)(tong)(tong)制(zhi)(zhi)藥(yao)二廠(chang))優質(zhi)資(zi)源,并吸收民營(ying)資(zi)本南(nan)通(tong)(tong)(tong)綜藝投資(zi)有(you)限公司以及自(zi)然(ran)人投資(zi)設立。2010年2月在深交(jiao)所(suo)中小板掛牌上(shang)市(shi),股(gu)票簡稱:精華(hua)制(zhi)(zhi)藥(yao),證券代號:002349。
公司已有(you)(you)(you)(you)(you)60多(duo)年的制(zhi)藥(yao)(yao)(yao)(yao)歷史,是(shi)一家綜合(he)(he)性的現代化(hua)(hua)GMP制(zhi)藥(yao)(yao)(yao)(yao)有(you)(you)(you)(you)(you)限公司。目前擁(yong)有(you)(you)(you)(you)(you)7個(ge)子(zi)公司,是(shi)一家集中(zhong)(zhong)藥(yao)(yao)(yao)(yao)制(zhi)劑、中(zhong)(zhong)藥(yao)(yao)(yao)(yao)飲片、西(xi)(xi)藥(yao)(yao)(yao)(yao)制(zhi)劑、醫藥(yao)(yao)(yao)(yao)中(zhong)(zhong)間體、化(hua)(hua)學原料(liao)藥(yao)(yao)(yao)(yao)、生物制(zhi)藥(yao)(yao)(yao)(yao)、保(bao)(bao)健(jian)品(pin)等(deng)生產(chan)、銷(xiao)售和研發的綜合(he)(he)型(xing)制(zhi)藥(yao)(yao)(yao)(yao)企(qi)業集團。公司有(you)(you)(you)(you)(you)中(zhong)(zhong)西(xi)(xi)藥(yao)(yao)(yao)(yao)品(pin)種(zhong)200余(yu)種(zhong),中(zhong)(zhong)藥(yao)(yao)(yao)(yao)產(chan)品(pin)主要有(you)(you)(you)(you)(you)享譽海內外的經典名藥(yao)(yao)(yao)(yao)“五朵(duo)金花”王氏(shi)保(bao)(bao)赤(chi)丸(wan)、季德勝(sheng)蛇(she)藥(yao)(yao)(yao)(yao)片、正柴(chai)胡(hu)飲顆粒、大柴(chai)胡(hu)顆粒、金蕎(qiao)麥(mai)膠囊,以及(ji)固本咳喘片、暈可平糖漿(jiang)、精血補片等(deng),這些中(zhong)(zhong)藥(yao)(yao)(yao)(yao)品(pin)種(zhong)都有(you)(you)(you)(you)(you)著廣泛的歷史背景及(ji)深(shen)厚(hou)的文(wen)化(hua)(hua)底蘊,其中(zhong)(zhong)季德勝(sheng)蛇(she)藥(yao)(yao)(yao)(yao)片、王氏(shi)保(bao)(bao)赤(chi)丸(wan)制(zhi)作技藝均被列入國(guo)家非物質文(wen)化(hua)(hua)遺產(chan)。原料(liao)藥(yao)(yao)(yao)(yao)產(chan)品(pin)主要有(you)(you)(you)(you)(you)苯巴比妥(tuo)、撲米酮、氟(fu)(fu)尿嘧(mi)啶(ding)(ding)、保(bao)(bao)泰松、氟(fu)(fu)胞(bao)嘧(mi)啶(ding)(ding)、吡羅(luo)昔康、替諾昔康、丙硫氧嘧(mi)啶(ding)(ding)、非那西(xi)(xi)丁、雙嘧(mi)達莫以及(ji)其它醫藥(yao)(yao)(yao)(yao)中(zhong)(zhong)間體等(deng)。其中(zhong)(zhong)已有(you)(you)(you)(you)(you)10個(ge)品(pin)種(zhong)通(tong)(tong)過國(guo)家GMP認(ren)證,5個(ge)品(pin)種(zhong)通(tong)(tong)過歐盟CEP認(ren)證,2個(ge)品(pin)種(zhong)通(tong)(tong)過澳大利亞GMP認(ren)證,3個(ge)品(pin)種(zhong)通(tong)(tong)過墨西(xi)(xi)哥官方認(ren)證,4個(ge)品(pin)種(zhong)獲(huo)得美國(guo)DMF注(zhu)冊文(wen)件(jian) ,1個(ge)品(pin)種(zhong)獲(huo)得美國(guo)VMF注(zhu)冊文(wen)件(jian),并已通(tong)(tong)過美國(guo)FDA現場(chang)核查。
精(jing)華制藥(yao)將會以(yi)(yi)“成(cheng)為(wei)(wei)以(yi)(yi)傳(chuan)(chuan)世中藥(yao)為(wei)(wei)核心特色的(de)全國(guo)現代醫(yi)藥(yao)企業”為(wei)(wei)戰略(lve)(lve)目(mu)標,深入貫徹(che)《關于促進中醫(yi)藥(yao)傳(chuan)(chuan)承創(chuang)新(xin)發展的(de)意見》精(jing)神,聚焦“五朵金花”傳(chuan)(chuan)世中藥(yao)主(zhu)業為(wei)(wei)主(zhu),特色化學原料藥(yao)及(ji)化學制劑為(wei)(wei)輔的(de)“雙輪驅(qu)動”的(de)發展戰略(lve)(lve),依托品牌力和(he)渠道(dao)力,致(zhi)力于成(cheng)為(wei)(wei)以(yi)(yi)傳(chuan)(chuan)世中藥(yao)為(wei)(wei)核心特色的(de)全國(guo)現代醫(yi)藥(yao)企業。